No­var­tis is ring­ing in the new year with more job cuts, ac­cord­ing to New Jer­sey state doc­u­ments.

The phar­ma gi­ant is ax­ing 284 jobs in East Hanover, a town­ship about 24 miles away from New York City. The cuts, which span No­var­tis Ser­vices, No­var­tis Phar­ma­ceu­ti­cals and No­var­tis Cor­po­ra­tion, take ef­fect on Jan. 28, ac­cord­ing to a no­tice post­ed last month in New Jer­sey’s state Work­er Ad­just­ment and Re­train­ing No­ti­fi­ca­tion Act (WARN) sys­tem.

A range of po­si­tions will be af­fect­ed, ac­cord­ing to a spokesper­son, in­clud­ing: “roles in the for­mer Phar­ma­ceu­ti­cals and On­col­o­gy di­vi­sions, cer­tain func­tions of Glob­al Drug De­vel­op­ment, and cer­tain busi­ness units that were part of Cus­tomer Tech­nol­o­gy So­lu­tions, as well as in Com­mu­ni­ca­tions & En­gage­ment, Ethics Risk & Com­pli­ance, Fi­nance, Glob­al Se­cu­ri­ty, Le­gal, Pub­lic Af­fairs, and Peo­ple & Or­ga­ni­za­tion.”

CEO Vas Narasimhan is on a mis­sion to make No­var­tis a top-five play­er in the US by 2027. Ear­li­er this year, he re­vealed those plans would in­volve thou­sands of job cuts, com­bin­ing the on­col­o­gy and phar­ma units and fi­nal­ly de­cid­ing to spin off gener­ics unit San­doz. A spokesper­son told End­points ear­li­er this year that about 8,000 of 108,000 roles were on the line.

The com­pa­ny an­nounced just last month that the clo­sure of a site in Lib­er­tyville, IL would leave about 275 jobs on the chop­ping block, and in Oc­to­ber said it would cut around 400 jobs at its Dublin cam­pus by the end of 2024.

Last year, No­var­tis told the New Jer­sey Dai­ly Record that it sold off 62 acres of its for­mer 202-acre cam­pus in East Hanover, as it cre­at­ed a “more flex­i­ble work­place de­sign” that re­quires “few­er build­ings to ac­com­mo­date our em­ploy­ees’ work­spaces.”

“We rec­og­nize the im­pact these changes have on our peo­ple. The com­pa­ny is of­fer­ing sup­port for im­pact­ed as­so­ciates, in­clud­ing out­place­ment ser­vices and ca­reer coun­sel­ing, as well as sup­port find­ing new roles with­in the com­pa­ny,” the spokesper­son said on Mon­day.